Share on StockTwits

Analysts at Oppenheimer hoisted their target price on shares of ANI Pharmaceuticals (NASDAQ:ANIP) from $35.00 to $37.00 in a research report issued to clients and investors on Tuesday. Oppenheimer’s price objective suggests a potential upside of 26.15% from the stock’s previous close.

ANI Pharmaceuticals (NASDAQ:ANIP) traded down 1.21% during mid-day trading on Tuesday, hitting $29.33. 204,224 shares of the company’s stock traded hands. ANI Pharmaceuticals has a 52 week low of $5.99 and a 52 week high of $38.74. The stock has a 50-day moving average of $33. and a 200-day moving average of $30.18. The company has a market cap of $330.9 million and a P/E ratio of 213.60.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Monday, August 4th. The company reported ($0.21) EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.01 by $0.22. The company had revenue of $6.60 million for the quarter, compared to the consensus estimate of $7.95 million. The company’s quarterly revenue was up 8.0% on a year-over-year basis. On average, analysts predict that ANI Pharmaceuticals will post $1.26 earnings per share for the current fiscal year.

Several other analysts have also recently commented on the stock. Analysts at Zacks downgraded shares of ANI Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Tuesday, July 8th. They now have a $40.60 price target on the stock.

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company developing, manufacturing and marketing branded and generic prescription pharmaceuticals.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.